MX2007003162A - Composicion farmaceutica que comprende una dispersion solida con una matriz polimerica que comprende una fase continua de polidextrosa y una fase continua de un polimero distinto de la polidextrosa. - Google Patents

Composicion farmaceutica que comprende una dispersion solida con una matriz polimerica que comprende una fase continua de polidextrosa y una fase continua de un polimero distinto de la polidextrosa.

Info

Publication number
MX2007003162A
MX2007003162A MX2007003162A MX2007003162A MX2007003162A MX 2007003162 A MX2007003162 A MX 2007003162A MX 2007003162 A MX2007003162 A MX 2007003162A MX 2007003162 A MX2007003162 A MX 2007003162A MX 2007003162 A MX2007003162 A MX 2007003162A
Authority
MX
Mexico
Prior art keywords
polydextrose
continuous
phase
polymer
polymer matrix
Prior art date
Application number
MX2007003162A
Other languages
English (en)
Inventor
Thierry Breul
Michel Bedos
Isabel Ribeiro Dos Santos
Stephen Byard
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2007003162A publication Critical patent/MX2007003162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a una composicion farmaceutica solida que comprende una dispersion solida que contiene al menos un principio activo y una matriz polimerica farmaceuticamente aceptable. La invencion se caracteriza porque la matriz polimerica farmaceuticamente aceptable comprende una mezcla de (i) polidextrosa, en la forma de una fase continua de polidextrosa, a fin de favorecer la desintegracion de la composicion en un medio acuoso y (ii) al menos un polimero diferente a la polidextrosa, en la forma de una fase continua, mediante la cual la polidextrosa se encuentra en una concentracion de al menos 20% en peso y al menos un polimero diferente a la polidextrosa se encuentra en una concentracion de al menos 20% en peso en relacion al peso total de la matriz polimerica farmaceuticamente aceptable.
MX2007003162A 2004-09-17 2005-09-15 Composicion farmaceutica que comprende una dispersion solida con una matriz polimerica que comprende una fase continua de polidextrosa y una fase continua de un polimero distinto de la polidextrosa. MX2007003162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0409874A FR2875409B1 (fr) 2004-09-17 2004-09-17 Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
PCT/FR2005/002288 WO2006032762A2 (fr) 2004-09-17 2005-09-15 Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose

Publications (1)

Publication Number Publication Date
MX2007003162A true MX2007003162A (es) 2007-05-16

Family

ID=34948358

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003162A MX2007003162A (es) 2004-09-17 2005-09-15 Composicion farmaceutica que comprende una dispersion solida con una matriz polimerica que comprende una fase continua de polidextrosa y una fase continua de un polimero distinto de la polidextrosa.

Country Status (18)

Country Link
US (1) US9084730B2 (es)
EP (1) EP1791524B1 (es)
JP (1) JP5224812B2 (es)
KR (1) KR101342193B1 (es)
CN (2) CN101039657B (es)
AU (1) AU2005286396B2 (es)
BR (1) BRPI0515390A (es)
CA (1) CA2579673C (es)
EA (1) EA012850B1 (es)
FR (1) FR2875409B1 (es)
HK (1) HK1111608A1 (es)
IL (1) IL181773A0 (es)
MA (1) MA28858B1 (es)
MX (1) MX2007003162A (es)
NO (1) NO20071853L (es)
NZ (1) NZ553780A (es)
WO (1) WO2006032762A2 (es)
ZA (1) ZA200702214B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
CN103735515A (zh) * 2006-02-09 2014-04-23 默沙东公司 Cetp抑制剂的聚合物制剂
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
FR2921835B1 (fr) * 2007-10-05 2012-05-04 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage comprenant du polydextrose, procede pour sa preparation et utilisation pour enrober les formes solides ingerables
PE20091809A1 (es) 2008-04-17 2009-12-03 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
CN102078307B (zh) * 2009-12-01 2012-11-07 天津市汉康医药生物技术有限公司 一种盐酸决奈达隆固体分散体的药物组合物及其制备方法
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2011135582A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
WO2011135581A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
CA2798084A1 (en) 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
WO2012001673A1 (en) * 2010-06-28 2012-01-05 Mapi Pharma Holdings (Cyprus) Limited Amorphous form of dronedarone
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
US20130142849A1 (en) 2010-08-17 2013-06-06 Lupin Limited Controlled release formulations of dronedarone
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US9204667B2 (en) * 2010-12-01 2015-12-08 R.J. Reynolds Tobacco Company Smokeless tobacco pastille and injection molding process for forming smokeless tobacco products
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
JP2015507003A (ja) 2012-02-20 2015-03-05 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ ドロネダロンの二層錠剤
CN103054820B (zh) * 2012-08-22 2016-07-13 石药集团中奇制药技术（石家庄）有限公司 一种盐酸决奈达隆药物组合物及其制备方法
JP6514114B2 (ja) 2013-01-23 2019-05-15 アルデイラ セラピューティクス， インコーポレイテッド 毒性アルデヒド関連疾患および処置
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
SI3650014T1 (sl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2018046642A1 (en) * 2016-09-09 2018-03-15 Merck Patent Gmbh Process for the manufacture of a solid pharmaceutical adminstration form
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. PHARMACEUTICAL FORMULATIONS AND USES THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5456932A (en) * 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
CA2095776C (en) * 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5935600A (en) * 1993-09-10 1999-08-10 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing comestible unit and product therefrom
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
DE19938672C2 (de) 1999-08-06 2001-11-22 Biop Biopolymer Gmbh Verfahren zur Herstellung einer thermoplastischen Polymermischung auf Stärkebasis durch reaktive Extrusion
EP1401503B1 (en) * 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical

Also Published As

Publication number Publication date
NZ553780A (en) 2010-08-27
IL181773A0 (en) 2007-07-04
ZA200702214B (en) 2008-09-25
CA2579673C (fr) 2014-11-18
EP1791524A2 (fr) 2007-06-06
EP1791524B1 (fr) 2014-11-19
KR20070055601A (ko) 2007-05-30
CN101039657A (zh) 2007-09-19
FR2875409B1 (fr) 2010-05-07
EA200700658A1 (ru) 2007-08-31
HK1111608A1 (en) 2008-08-15
AU2005286396B2 (en) 2011-08-11
WO2006032762A2 (fr) 2006-03-30
EA012850B1 (ru) 2009-12-30
CN102247601A (zh) 2011-11-23
US20070243257A1 (en) 2007-10-18
CA2579673A1 (fr) 2006-03-30
KR101342193B1 (ko) 2013-12-16
AU2005286396A1 (en) 2006-03-30
BRPI0515390A (pt) 2008-07-22
US9084730B2 (en) 2015-07-21
CN101039657B (zh) 2012-07-18
JP2008513421A (ja) 2008-05-01
JP5224812B2 (ja) 2013-07-03
MA28858B1 (fr) 2007-09-03
FR2875409A1 (fr) 2006-03-24
NO20071853L (no) 2007-06-15
WO2006032762A3 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
MX2007003162A (es) Composicion farmaceutica que comprende una dispersion solida con una matriz polimerica que comprende una fase continua de polidextrosa y una fase continua de un polimero distinto de la polidextrosa.
SI1933809T1 (sl) Sestavki za mazalno dajanje
PL1713446T3 (pl) Nielamelarne trójskładnikowe kompozycje lipidów
MX2009000035A (es) Formulaciones de agente activo, procedimientos de preparacion y procedimientos de uso.
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
WO2007056424A3 (en) Controlled-release emulsion compositions
WO2007072189A3 (en) A silylated polymer emulsion and its preparation method and uses thereof
RS20050066A (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
MY122668A (en) Liquid compositions comprising stable emulsion of small particle skin benefit agent
JP2009516717A5 (es)
TW200740427A (en) Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
BR9809865A (pt) Fixador de perfume, perfume e produto base misturados com o mesmo, e, produto perfumado.
WO2007014328A3 (en) Compositions and methods for emulsifying a perfluorocarbon with an oxygen-carrying surfactant
BR0005034A (pt) Composição herbicida
ATE430189T1 (de) Wasch- oder reinigungsmittel
BRPI0412391A (pt) formulação farmacêutica compreendendo levotiroxina sódica
TW200722075A (en) Propofol-containing fat emulsion
BRPI0500623A (pt) composição para regular o crescimento de insetos
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
MX2008010879A (es) Composiciones farmaceuticas de sodio de fluvastatina.
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
RS51578B (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING TELITROMYCIN
ZA200705660B (en) Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate
UA93540C2 (ru) Фармацевтическая композиция для аэрозольного распыления c двумя действующими веществами и, по меньшей mepe, одним поверхностно-активным веществом
BR0212751A (pt) Composição detergente sólida, e, barra detergente

Legal Events

Date Code Title Description
FG Grant or registration